C. Difficile

Check out the latest studies, management strategies, patient advocacy, and other important news involving this condition.

A study presented at ESCMID aims to understand ribotype 955 as a new challenge in C difficile management.

A study presented at the Society for Healthcare Epidemiology of America (SHEA) conference assesses the link between antibiotic use and C difficile infection in Tennessee.

A study, presented at the Society for Healthcare Epidemiology of America (SHEA) conference, assesses laxative administration before CDI testing in Veteran Affairs (VA) hospitals and explores the demographic and contextual factors with non-adherence to guidelines.

Incidence of hospital-onset Clostridioides difficile infection differed between hospitals that implemented the CDC prevention strategies and those that did not, but not necessarily because of the strategies.

This annual event hosted by The Peggy Lillis Foundation (PLF) released their full agenda for advocacy and education that will be happen next week in Washington DC.

Community acquired pneumonia is often inappropriately diagnosed in hospital admissions, particularly among older adults with dementia, and can lead to in-hospital antibiotic-associated adverse events, such as Clostridioides difficile.

A study on the impact of guidelines on reducing hospital-onset CDI incidence.

FDA authorizes Ito Invivyd’s pemivibart (Pemgarda), insights on Sofosbuvir levels in pregnant women, the effectiveness of fidaxomicin vs vancomycin for CDI treatment, and more this week from Contagion.

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.

This week learn more about CDC's strategies to reduce waterborne diseases; the US change to a trivalent influenza vaccine; new data for Merck's pneumococcal vaccine; and how PCR testing can influence a patient diagnosis and outcome.

The impact of polymerase chain reaction (PCR) testing on patient outcomes.

Successful phase 2 trial leads to phase 3 trial towards managing C difficile.

This week, the FDA-approved antiretroviral lenacapavir as it showed treatment benefits; Oral Vancomycin Prophylaxis was explored for preventing C difficile in stem cell transplant recipients; Research into the after-effects of SARS-CoV-2 (PASC) uncovers biomarkers for post-infection sequelae; Chronic hepatitis B worsens COVID-19 outcomes, and cabotegravir ultra-long-acting (CABULA) has shown positive results.

Study dives into the complexities of using Oral Vancomycin Prophylaxis to combat Clostridioides difficile in hematopoietic stem cell transplantation recipients with insights from researcher Alexander Vartanov, MD.

The American Gastroenterological Association recommends fecal microbiota-based therapies for recurrent or severe C difficile infections and other gastrointestinal issues.

This week, increased risk of long COVID in individuals who have tested positive for the virus, advancements in the preservation of the microbiome offer new strategies for healthcare-associated infections (HAIs), FDA-approved GSK's bepirovirsen signaling the company's goal to cure viral hepatitis, CDC considers changing 5-day COVID isolation guideline, and the first victim of the Alaskapox virus highlights the critical need for increased research into emerging infectious diseases.

Advancements in microbiome preservation offer new solutions for HAI.

Study encourages enhancing protocols to clean and disinfect hospital beds and healthcare environments to stop the spread of healthcare-associated infections.

Topline data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile infection (CDI) vaccine.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

With the addition of 2 new live biotherapeutic products, a clinician reviews the application, storage and administration techniques for them.

New data showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment, ADS024.

This market has seen a flurry of activity, as shown by a review of the latest agents.

This class of medications were associated with a greater risk of Clostridioides difficile infection (CDI).

Company plans to start recruiting for its REPREVE study this year.

Excess death risks from GI diseases, above pre-pandemic patterns, were largest for C difficile colitis, followed by GI hemorrhage, ulcers, and colorectal cancer.

Investigators explored the makeup of antibiotic resistant genes after administration of the live biotherapeutic product, Rebyota (fecal microbiota, Live-jslm), to see what differences would be discovered.

In this week's infectious disease news, the Novavax COVID-19 booster gets authorized in the US; Moderna reports topline data on its influenza-COVID-19 combination vaccine; the differences between live biotherapeutic products and conventional FMTs; and the influence of alcohol on hepatitis C treatment.